Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Lyons

Pulmonary Disease Rochester, NY Medical Doctor

NPI 1083722714 CMS profile 185045

1561 Long Pond Rd, Suite 406, Rochester, NY 14626

Open in the dashboard

General payments

$54,619

143 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Lyons of Rochester, NY is reported in the CMS Open Payments database as having received $54,619 across 143 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $713 34
2024 General $218 13
2023 General $9,956 34
2022 General $4,303 20
2021 General $21,030 23
2020 General $18,380 18
2019 General $20 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Lyons
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Jason Lyons were reported at $713. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Jason Lyons Pulmonary Disease median Middle half National median
2019 $20 $377 $109–$1,340 $163
2020 $18,380 $230 $56–$907 $114
2021 $21,030 $269 $68–$1,072 $132
2022 $4,303 $390 $100–$1,457 $149
2023 $9,956 $419 $114–$1,659 $160
2024 $218 $476 $123–$1,818 $164
2025 $713 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $53,512 92 payments
  2. Electromed, Inc. $210 12 payments
  3. AstraZeneca Pharmaceuticals LP $151 9 payments
  4. AbbVie, Inc. $125 2 payments
  5. Jazz Pharmaceuticals Inc. $80 3 payments
  6. Grifols USA, LLC $63 3 payments
  7. Astellas Pharma US Inc $48 2 payments
  8. Genzyme Corporation $47 2 payments
  9. Regeneron Healthcare Solutions, Inc. $41 2 payments
  10. Janssen Pharmaceuticals, Inc $39 2 payments
  11. Other $304 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $51,400 17 payments
  2. Food and Beverage $3,148 124 payments
  3. Travel and Lodging $54 1 payment
  4. Education $17 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $39,645 42 payments
  2. ANORO ELLIPTA $3,769 6 payments
  3. NUCALA $773 39 payments
  4. SMARTVEST $210 12 payments
  5. VRAYLAR $125 2 payments
  6. BREZTRI $97 6 payments
  7. XYWAV $80 3 payments
  8. Prolastin-C Liquid $63 3 payments
  9. DUPIXENT Immunology $47 2 payments
  10. DUPIXENT Inflammation And Immunology $41 2 payments
  11. Other $594 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

374

Median for Pulmonary Disease: 936

Drug cost

$335,090

Median for Pulmonary Disease: $487,987

Branded share of claims

69.5%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prolastin C Alpha-1-Proteinase Inhibitor Brand 22 $228,675
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 122 $85,562
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 25 $12,336
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 44 $6,589
Albuterol Sulfate Hfa Albuterol Sulfate Brand 47 $1,042
Azithromycin Generic 91 $834
Prednisone Generic 23 $53

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$30,254

Medicare's payments for the services billed

Medicare patients

144

Average age 71

Services billed

373

81 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
COPD 44%
Diabetes 39%
Heart failure 38%
Ischemic heart disease 35%
Depression 35%
Chronic kidney disease 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $57
$57 — —
WAKIX
  • Harmony Biosciences LLC $22
$22 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $21
$21 122 —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $15
$15 — —
YUPELRI
  • Mylan Specialty L.P. $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

143 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record